Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Human Microbiome, Diet and Cancerogenesis
share announcement

Human Microbiome, Diet and Cancerogenesis

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: 31 May 2025 | Viewed by 4480

Special Issue Editor

Prof. Dr. Ewa Brzeziańska-Lasota

E-Mail Website
Guest Editor
Department of Biomedicine and Genetics, Medical University of Lodz, 251 Str. Pomorska, 92-213 Lodz, Poland
Interests: lung cancer; gastric cancer; cervical cancer; autoimmune lung diseases; COPD; biomarkers; molecular diagnostics; epigenetics; exosomes; oncobiome

Special Issue Information

Dear Colleagues,

Many research results show that the microbiome determines health, but dysbiosis plays a pivotal role in the occurrence of many human diseases, including cancer development. The relationship between microorganisms and cancer is complex and involves the functional interaction between the oncobiome and numerous cell signaling pathways. The mechanism of the specific communication between microbial communities, human immune cells and signaling network plays an important role in cancer development as well as in cancer therapy. These interactions occur through epigenome modifications, which are strongly related to cancer progression. Therefore, the current strategies for microbiome-based modulation, such as dietary interventions’ influence on the microbiome axis, offer a tool for preventing cancer or improving various cancer treatment methods. The current interventions especially targeting intestinal microorganisms, such as the supplementation of prebiotics, probiotics and postbiotics or individual diet pattern’s influence on epigenome and signaling pathways, have achieved satisfactory results especially in improving cancer diagnosis and therapy.

This Special Issue of Cancers aims to highlight the significant role of research on the interaction of the microbiome/oncobiome with cell signaling pathways, immune response mechanisms and epigenetic modulations (e.g., DNA methylation, mRNA/non-coding RNA expression modulation) in response to dietary modifications in patients with cancer. The research results that focus on dysbiosis-linked epigenetic modification and epigenetic modification under nutrition-based interventions in patients with cancer will be extremely exciting. The aspect of epigenome and oncobiota crosstalk as a predictive biomarker for cancer disease and therapy should be pointed out.

In this Special Issue, original research articles, meta-analyses and reviews on the aforementioned topics are welcome. 

I look forward to receiving your contributions.

Prof. Dr. Ewa Brzeziańska-Lasota
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • microbiota
  • dysbiosis
  • oncobiome
  • cell disruptors
  • cell signaling
  • epigenetics
  • diet
  • dietary intervention
  • microbiota disorders
  • cancerogenesis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

23 pages, 8488 KiB  
Article
Pan-Cancer Insights: A Study of Microbial Metabolite Receptors in Malignancy Dynamics
by Nikolas Dovrolis, Michail Spathakis, Alexandra R. Collins, Varun Kumar Pandey, Muhammad Ikhtear Uddin, Donald D. Anderson, Tetiana Kaminska, Vasilis Paspaliaris and George Kolios
Cancers 2024, 16(24), 4178; https://doi.org/10.3390/cancers16244178 - 15 Dec 2024
Viewed by 1580
Abstract
Background/Objectives: The role of the gut microbiome in cancer biology has become an increasingly prominent area of research, particularly regarding the role of microbial metabolites and their receptors (MMRs). These metabolites, through the various gut–organ axes, have been proven to influence several pathogenetic [...] Read more.
Background/Objectives: The role of the gut microbiome in cancer biology has become an increasingly prominent area of research, particularly regarding the role of microbial metabolites and their receptors (MMRs). These metabolites, through the various gut–organ axes, have been proven to influence several pathogenetic mechanisms. This study conducted a comprehensive pan-cancer analysis of MMR transcriptomic profiles across twenty-three cancer types, exploring the mechanisms through which they can influence cancer development and progression. Methods: Utilizing both cancer cell lines from CCLE (Cancer Cell Line Encyclopedia) and human tumor samples from TCGA (The Cancer Gene Atlas), we analyzed 107 MMRs interacting with microbial metabolites such as short-chain fatty acids, bile acids, indole derivatives, and others while studying their interactions with key known cancer genes. Results: Our results revealed that certain MMRs, such as GPR84 and serotonin receptors, are consistently upregulated in various malignancies, while others, like ADRA1A, are frequently downregulated, suggesting diverse roles in cancer pathophysiology. Furthermore, we identified significant correlations between MMR expression and cancer hallmark genes and pathways, including immune evasion, proliferation, and metastasis. Conclusions: These findings suggest that the interactions between microbial metabolites and MMRs may serve as potential biomarkers for cancer diagnosis, prognosis, and therapy, highlighting their therapeutic potential. This study underscores the significance of the microbiota–cancer axis and provides novel insights into microbiome-based strategies for cancer treatment. Full article
(This article belongs to the Special Issue Human Microbiome, Diet and Cancerogenesis)
►▼ Show Figures

Graphical abstract

24 pages, 3187 KiB  
Article
Effect of a Novel Food Rich in Miraculin on the Oral Microbiome of Malnourished Oncologic Patients with Dysgeusia
by Julio Plaza-Diaz, Francisco Javier Ruiz-Ojeda, Bricia López-Plaza, Marco Brandimonte-Hernández, Ana Isabel Álvarez-Mercado, Lucía Arcos-Castellanos, Jaime Feliú-Batlle, Thomas Hummel, Samara Palma-Milla and Angel Gil
Cancers 2024, 16(19), 3414; https://doi.org/10.3390/cancers16193414 - 8 Oct 2024
Cited by 1 | Viewed by 1747
Abstract
Background/Objectives: Dysgeusia contributes to the derangement of nutritional status in patients with cancer as well as worsening the quality of life. There has been a lack of effective treatments for taste disorders provided by the pharmaceutical industry. Methods: This was a pilot randomized, [...] Read more.
Background/Objectives: Dysgeusia contributes to the derangement of nutritional status in patients with cancer as well as worsening the quality of life. There has been a lack of effective treatments for taste disorders provided by the pharmaceutical industry. Methods: This was a pilot randomized, parallel, triple-blind, and placebo-controlled intervention clinical trial in which 31 malnourished patients with cancer and dysgeusia receiving antineoplastic treatment were randomized into three arms [standard dose of DMB (150 mg DMB/tablet), high dose of DMB (300 mg DMB/tablet) or placebo (300 mg freeze-dried strawberry)] for three months. Patients consumed a DMB or placebo tablet before each main meal. Using the nanopore methodology, we analyzed the oral microbiome of patients with cancer using saliva samples. Results: All patients with cancer and dysgeusia had dysbiosis in terms of lower bacterial diversity and richness. DMB consumption was associated with changes in oral microbiome composition. Neither selected bacteria nor taste perception, type of diet, and cytokine levels were associated with mucositis. Likewise, alcohol and tobacco consumption as well as general and digestive toxicity due to systemic therapy were not associated with specific changes of the oral microbiome, according to logistic binary regression. The standard dose of DMB resulted in a lower abundance of Veillonella compared with the high DMB dose and placebo at 3 months after intervention with DMB. In particular, some species such as Streptococcus parasanguinis, Veillonella parvula, and Streptococcus mutans were less abundant in the DMB standard-dose group. Additionally, the consumption of a standard dose of DMB revealed a negative association between the concentrations of TNF-α and the abundance of species such as Streptococcus thermophilus, Streptococcus pneumoniae, Streptococcus dysgalactiae and Streptococcus agalactiae. Conclusions: Accordingly, regular DMB consumption could modify the oral microbiome in patients with cancer and dysgeusia, which may contribute to maintaining an appropriate immune response. However, as the present pilot study involved a small number of participants, further studies are necessary to draw robust conclusions from the data. Full article
(This article belongs to the Special Issue Human Microbiome, Diet and Cancerogenesis)
►▼ Show Figures

Figure 1

Review

Jump to: Research

25 pages, 1167 KiB  
Review
Optimizing Cancer Treatment Through Gut Microbiome Modulation
by Kyuri Kim, Mingyu Lee, Yoojin Shin, Yoonji Lee and Tae-Jung Kim
Cancers 2025, 17(7), 1252; https://doi.org/10.3390/cancers17071252 - 7 Apr 2025
Viewed by 786
Abstract
The gut microbiome plays a pivotal role in modulating cancer therapies, including immunotherapy and chemotherapy. Emerging evidence demonstrates its influence on treatment efficacy, immune response, and resistance mechanisms. Specific microbial taxa enhance immune checkpoint inhibitor efficacy, while dysbiosis can contribute to adverse outcomes. [...] Read more.
The gut microbiome plays a pivotal role in modulating cancer therapies, including immunotherapy and chemotherapy. Emerging evidence demonstrates its influence on treatment efficacy, immune response, and resistance mechanisms. Specific microbial taxa enhance immune checkpoint inhibitor efficacy, while dysbiosis can contribute to adverse outcomes. Chemotherapy effectiveness is also influenced by microbiome composition, with engineered probiotics and prebiotics offering promising strategies to enhance drug delivery and reduce toxicity. Moreover, microbial metabolites, such as short-chain fatty acids, and engineered microbial systems have shown potential to improve therapeutic responses. These findings underscore the importance of personalized microbiome-based approaches in optimizing cancer treatments. Full article
(This article belongs to the Special Issue Human Microbiome, Diet and Cancerogenesis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop